UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043402
Receipt number R000049553
Scientific Title Monitoring of influenza vaccine effectiveness among Japanese children (2020/21 - 2026/27 season)
Date of disclosure of the study information 2021/02/22
Last modified on 2024/01/12 16:41:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Monitoring of influenza vaccine effectiveness among Japanese children (2020/21 - 2026/27 season)

Acronym

Monitoring of influenza vaccine effectiveness among Japanese children (2020/21 - 2026/27 season)

Scientific Title

Monitoring of influenza vaccine effectiveness among Japanese children (2020/21 - 2026/27 season)

Scientific Title:Acronym

Monitoring of influenza vaccine effectiveness among Japanese children (2020/21 - 2026/27 season)

Region

Japan


Condition

Condition

Influenza

Classification by specialty

Infectious disease Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

We aim to monitor influenza vaccine effectiveness among Japanese children.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Laboratory-confirmed influenza

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

6 months-old <=

Age-upper limit

6 years-old >

Gender

Male and Female

Key inclusion criteria

For 2020/21 to 2022/23 season
1) Children with influenza-like illness (ILI) who visited collaborating pediatric clinics in Osaka/Fukuoka prefecture, Japan, during the 2020/21, 2021/22 and 2022/23 influenza season
2) Aged less than 3 years at the time of visit
3) Those who visited the clinics within 7 days after onset of fever (38.0 degree)

For 2023/24 to 2026/27 season
1) Children with influenza-like illness (ILI) who visited collaborating pediatric clinics in Osaka/Fukuoka prefecture, Japan, during the 2020/21, 2021/22 and 2022/23 influenza season
2) Aged less than 6 years at the time of visit
3) Those who visited the clinics within 7 days after onset of fever (38.0 degree)

Key exclusion criteria

Subjects are excluded if they:
- are aged less than 6 months, as of the last October 1st before each season
- have a history of anaphylaxis after influenza vaccination
- had been administered influenza antivirals for the current ILI
- experienced the current ILI during the hospitalization
- are institutionalized
- are non-residents in Osaka/Fukuoka prefecture, Japan
- are judged to be inappropriate for participation by doctors in charge

Target sample size

5250


Research contact person

Name of lead principal investigator

1st name Wakaba
Middle name
Last name Fukushima

Organization

Osaka Metropolitan University Graduate School of Medicine

Division name

Department of Public Health

Zip code

545-8585

Address

1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

TEL

06-6645-3756

Email

wakaba@omu.ac.jp


Public contact

Name of contact person

1st name Wakaba
Middle name
Last name Fukushima

Organization

Osaka Metropolitan University Graduate School of Medicine

Division name

Department of Public Health

Zip code

545-8585

Address

1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

TEL

06-6645-3756

Homepage URL


Email

wakaba@omu.ac.jp


Sponsor or person

Institute

Osaka Metropolitan University

Institute

Department

Personal name



Funding Source

Organization

Ministry of Health, Labour and Welfare, Japan

Organization

Division

Category of Funding Organization

Japanese Governmental office

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethical Committee of Osaka Metropolitan University Graduate School of Medicine

Address

Abeno Medix 6F, 1-2-7, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan

Tel

06-6645-3456

Email

gr-a-knky-ethics@omu.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪公立大学大学院医学研究科公衆衛生学(大阪府)、大阪健康安全基盤研究所(大阪府)、ふじおか小児科(大阪府)、松下こどもクリニック(大阪府)、くぼたこどもクリニック(大阪府)、八木小児科(大阪府)、高崎小児科医院(福岡県)、しんどう小児科医院(福岡県)、きよまつ小児科医院(福岡県)


Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 22 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

424

Results

Vaccine effectiveness
2022/23 season: 77% for 1 dose, 2% for 2 doses

Results date posted

2024 Year 01 Month 12 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 10 Month 01 Day

Date of IRB

2020 Year 10 Month 01 Day

Anticipated trial start date

2023 Year 01 Month 23 Day

Last follow-up date

2027 Year 06 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

1) Study design: case-control study (test-negative design)
2) Cases and controls: cases are subjects with positive results for influenza tested by real-time reverse transcription polymerase chain reaction using nasal discharge specimen, whereas controls are subjects with negative results
3) Exposure: history of influenza vaccination during the each season


Management information

Registered date

2021 Year 02 Month 21 Day

Last modified on

2024 Year 01 Month 12 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049553


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name